Modeling of presymptomatic and symptomatic stages of Parkinsonism in MPTP-treated mice: heart contraction adrenergic regulation and catecholamines content in blood

R2I2 was predictive of endpoint independent of EPS result, LVEF or QRS duration (Cox model p = 0.003). Using a predefined cut-off R2I2 value of ≥1.03 identified patients with a significantly higher risk of ventricular arrhythmia/SCD (63%) compared with R2I2 b1.03 (18%) (p b 0.0001). Conclusions: The R2I2, replicating a predefined technique, identified patients at very high risk of developing ventricular arrhythmias. R2I2 is a straightforward, potentially non-invasive test that could add considerable value to existing sudden cardiac death risk markers.